Daclatasvir and Lorbrena

In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.

Lorlatinib may significantly decrease the blood levels of daclatasvir, which may reduce its effectiveness in treating hepatitis C. Talk to your doctor if you have any questions or concerns. Your doctor may already be aware of the interaction, but has determined that this is the best course of treatment for you and has taken appropriate precautions or made dose adjustments and is monitoring you closely for any potential complications. Your doctor may also be able to prescribe alternatives that do not interact. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.

ADJUST DOSE: Coadministration with moderate inducers of CYP450 3A4 may significantly decrease the plasma concentrations of daclatasvir, which is primarily metabolized by the isoenzyme. In 17 healthy volunteers, administration of daclatasvir 120 mg daily for 4 days during concomitant treatment with the moderate CYP450 3A4 inducer efavirenz (600 mg once daily for 14 days) decreased daclatasvir peak plasma concentration (Cmax), systemic exposure (AUC) and trough plasma concentration (Cmin) by 33%, 63% and 17%, respectively, compared to administration of daclatasvir alone at 60 mg daily for 4 days. Linear dose scaling predicted that an increase in the daclatasvir dosage to 90 mg daily when used with efavirenz or other moderate CYP450 3A4 inducers would result in an AUC comparable to that produced by daclatasvir alone at 60 mg daily.

MANAGEMENT: Given the risk of reduced viral susceptibility and resistance development associated with subtherapeutic antiviral drug levels, an increase in the dosage of daclatasvir to 90 mg once daily is recommended when used with moderate CYP450 3A4 inducers.

Daclatasvir

Generic Name: daclatasvir

Brand name: Daklinza

Synonyms: n.a.

What is Daclatasvir?

Lorbrena

Generic Name: lorlatinib

Brand name: Lorbrena

Synonyms: n.a.

What is Lorbrena?